(Total Views: 167)
Posted On: 07/21/2020 1:15:47 PM
Post# of 145205

$RFL News Article - Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) https://marketwirenews.com/news-releases/rafa...37943.html


My Twitter: WhyteStocks